Also known as:Rybelsus· brand nameOral semaglutide· formulation name
Type 2 diabetessemaglutide also has we…
Semaglutide (oral)
Evidence levelLate-stage human
Human evidenceSubstantial
Regulatory statusAuthorised products exist
What you need to know in 20 seconds
What is it?
GLP-1 receptor agonist peptide analogue
Research focus
Type 2 diabetes; semaglutide also has weight-management evidence in other authorised formulations.
Human evidence
Oral semaglutide now has strong human evidence across obesity and cardiovascular outcomes. OASIS 4 found -13.6% mean weight change with oral semaglutide 25 mg versus -2.2% placebo at week 64, while SOUL showed fewer major cardiovascular events with oral semaglutide in high-risk type 2 diabetes.
Regulatory status
Authorised oral semaglutide products now include Rybelsus for type 2 diabetes and oral Wegovy tablets for adult weight management in current U.S./EU records; exact indication, strength and jurisdiction must be stated.
Main limitations
Equivalence across oral formulations/strengths or use outside the authorised product, population and indication.
Safety
GI adverse effects; risks and contraindications are detailed in authorised product information.
i
Oral semaglutide now has strong human evidence across obesity and cardiovascular outcomes. OASIS 4 found -13.6% mean weight change with oral semaglutide 25 mg versus -2.2% placebo at week 64, while SOUL showed fewer major cardiovascular events with oral semaglutide in high-risk type 2 diabetes.
What the evidence actually supports
✓Strong human efficacy evidence for the studied regimen; keep regulatory/product context explicit.
✓Keep oral Wegovy obesity evidence distinct from Rybelsus diabetes evidence on the same canonical oral-semaglutide page.
✓Strong second outcome that moves the oral-semaglutide page beyond weight/glycaemia alone.
What is not established / key limitations
×GI adverse events were frequent; the 50 mg study regimen should not be confused with other oral semaglutide doses/indications.
×This effect size cannot be transferred to lower-dose oral diabetes formulations.
×SOUL used up to 14 mg oral semaglutide in T2D; it is not the same regimen/population as OASIS 4 obesity treatment.
Route / formulation boundaryRybelsus, oral Wegovy and injectable semaglutide are not interchangeable formulations. Trial doses and currently labelled commercial tablet strengths must be kept separate.
Identity / data-quality noteUse the canonical compound identity and studied formulation when interpreting evidence.
Dosing evidence statusVerified dosing evidence added. UK licensed oral semaglutide dosing — current formulation example. See dosing_evidence records for route, regimen, population, duration and source.
Evidence rule: WhichPeps keeps human, animal, laboratory, regulatory and product/formulation evidence distinct. Common names help people find the page; they do not change the underlying scientific identity.
